M6A modification in cardiovascular disease: With a focus on programmed cell death

Li, Wen; Liu, Yao; Xu, Runchun; Zong, Ying; Li, He; Hu, Jun; Li, Guohua

doi:10.1016/j.gendis.2023.05.023

Cited by 2 publications

(2 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The extent of m 6 A methylation is primarily determined by the dynamic action of writers and erasers ( Li et al, 2023 ). Key components of the writer complex include METTL3, METTL14, WTAP, and RBM15, while FTO and ALKBH5 are involved in demethylation processes ( Luo et al, 2023 ).…”

Section: Resultsmentioning

confidence: 99%

Expression patterns of m6A RNA methylation regulators under apoptotic conditions in various human cancer cell lines

ALASAR,

SAĞLAM,

VATANSEVER

et al. 2024

Turkish Journal of Biology

View full text Add to dashboard Cite

Background/aim Cancer is a complex disease that involves both genetic and epigenetic factors. While emerging evidence clearly suggests that changes in epitranscriptomics play a crucial role in cancer pathogenesis, a comprehensive understanding of the writers, erasers, and readers of epitranscriptomic processes, particularly under apoptotic conditions remains lacking. The aim of this study was to uncover the changes in the expression of m 6 A RNA modifiers under apoptotic conditions across various cancer cell lines. Materials and methods Initially, we quantified the abundance of m 6 A RNA modifiers in cervical (HeLa and ME180), breast (MCF7 and MDA-MB-231), lung (A549 and H1299), and colon (Caco-2 and HCT116) cancer cell lines using qPCR. Subsequently, we induced apoptosis using cisplatin and tumor necrosis factor-alpha (TNF-α) to activate intrinsic and extrinsic pathways, respectively, and assessed apoptosis rates via flow cytometry. Further, we examined the transcript abundance of m 6 A RNA modifiers under apoptotic conditions in cervical, breast, and lung cancer cell lines using qPCR. Results Overall, treatment with cisplatin increased the abundance of m 6 A modifiers, whereas TNF-α treatment decreased their expression in cervical, breast, and lung cancer cell lines. Specifically, cisplatin-induced apoptosis, but not TNF-α-mediated apoptosis, resulted in decreased abundance of METTL14 and FTO transcripts. Additionally, cisplatin treatment drastically reduced the abundance of IGF2BP2 and IGF2BP3 readers. Conclusion These results suggest that the differential response of cancer cells to apoptotic inducers may be partially attributed to the expression of m 6 A RNA modifiers.

show abstract

Section: Resultsmentioning

confidence: 99%

Expression patterns of m6A RNA methylation regulators under apoptotic conditions in various human cancer cell lines

ALASAR,

SAĞLAM,

VATANSEVER

et al. 2024

Turkish Journal of Biology

View full text Add to dashboard Cite

show abstract

“…The extent of m 6 A methylation is primarily determined by a dynamic action of writers and erasers (W. Li et al, 2023). The key components of the writer complex are METTL3, METTL14, WTAP and RBM15 among others while FTO and ALKBH5 orchestrate demethylation (Luo et al, 2023).…”

Section: Abundance Of Transcripts Of M 6 a Writers And Erasers Is Der...mentioning

confidence: 99%

Expression patterns of m⁶A RNA methylation regulators under apoptotic conditions in various human cancer cell lines

Akçaöz-Alasar,

Sağlam,

Vatansever

et al. 2023

Preprint

View full text Add to dashboard Cite

The emerging evidence suggests that epitranscriptomics changes play a crucial role in the pathogenesis of cancer. However, expression patterns of m6A RNA modifiers under apoptotic conditions are unknown. We measured the transcript abundance of m6A RNA modifiers under cisplatin- and tumor necrosis factor alpha (TNF-α)-induced apoptotic conditions. In general, the abundance of m6A modifiers is increased upon cisplatin treatment whereas TNF-α treatment has led to a reduction in their expression. Specifically, cisplatin-induced apoptosis, but not TNF-α mediated apoptosis, lowered the abundance of METTL14 and FTO transcripts. Additionally, cisplatin treatment plummeted the abundance of IGF2BP2 and IGF2BP3 readers following cisplatin treatment. These results suggest that differential response of cancer cells to apoptotic inducers could be partially due to m6A RNA modifiers.

show abstract

M6A modification in cardiovascular disease: With a focus on programmed cell death

Cited by 2 publications

References 137 publications

Expression patterns of m6A RNA methylation regulators under apoptotic conditions in various human cancer cell lines

Expression patterns of m6A RNA methylation regulators under apoptotic conditions in various human cancer cell lines

Expression patterns of m⁶A RNA methylation regulators under apoptotic conditions in various human cancer cell lines

Contact Info

Product

Resources

About